| アブストラクト | ABSTRACT: OBJECTIVE: Pancreatic cancer (PC) is often preceded by elevated blood glucose levels and new-onset diabetes (NOD) may provide an opportunity for earlier detection. However, PC accounts for less than 1% of diabetes cases, making routine imaging of all patients with NOD impractical. We aimed to compare the diagnostic performance of the Enriching New-Onset Diabetes for Pancreatic Cancer (EndPAC), Boursi and Baecker models in British primary care patients with NOD and to adapt the models for use at the time of diabetes diagnosis. DESIGN: Cross-sectional analysis of a retrospective cohort. SETTING: We analysed routinely collected electronic primary care health records from the UK Clinical Practice Research Datalink. PARTICIPANTS: Among 197 092 patients with NOD, 901 (0.46%) were diagnosed with PC within 3 years of the diagnosis. Included were patients aged 50-90 years with NOD diagnosed between 2002 and 2018. Inclusion also required at least one valid glycaemic measurement at diabetes diagnosis and either 3 years of follow-up or death within that period. PRIMARY AND SECONDARY OUTCOME MEASURES: The primary outcome was discrimination of the original and adapted models, measured by area under the receiver operating curve (AUC). Secondary outcomes included model calibration and threshold-specific diagnostic performance for the adapted Boursi model. RESULTS: In its original form, the Boursi model showed the highest performance (AUC 0.78; 95% CI 0.76 to 0.80). After adaptation, the EndPAC score achieved an AUC of 0.69 (95% CI 0.67 to 0.72), Boursi 0.76 (95% CI 0.74 to 0.78) and Baecker 0.77 (95% CI 0.75 to 0.79) in the split-sample validation cohort. CONCLUSIONS: After adaptation, when restricted to parameters available at the time of NOD diagnosis, with imputed missing values, the Boursi and Baecker models performed similarly, while the EndPAC score, which uses only three variables, discriminated less well. Each model has distinct strengths; combining them may improve patient selection for further diagnostic evaluation. The adapted models were validated internally only and require external validation before clinical use. These findings support continued investigation of risk-based strategies for PC detection in primary care as part of a stepwise diagnostic pathway. |
| 組織名 | Department of Medical and Surgical Specialties, University of Fribourg Faculty of;Science and Medicine, Fribourg, Switzerland dr.mellenthin@hin.ch.;Family Medicine, Arztpraxis am Bager, Schmitten, Switzerland.;Basel Pharmacoepidemiology Unit, University of Basel, Basel, Switzerland.;Hospital Pharmacy, University Hospital Basel, Basel, Switzerland.;Boston Collaborative Drug Surveillance Program, Boston University, Boston,;Massachusetts, USA.;Science and Medicine, Fribourg, Switzerland.;Surgery, HFR Fribourg Cantonal Hospital, Fribourg, Switzerland.;Department of Visceral Surgery and Medicine, Inselspital University Hospital;Bern, Bern, Switzerland.;University of Basel Faculty of Medicine, Basel, Switzerland. |